Orchid Pharma Limited Asset Resilience Ratio
Orchid Pharma Limited asset resilience ratio. Orchid Pharma Limited (ORCHPHARMA) has an Asset Resilience Ratio of 4.03% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Orchid Pharma Limited liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Orchid Pharma Limited (2004–2026)
Asset resilience ratio of Orchid Pharma Limited from 2004 to 2026. This chart shows how Orchid Pharma Limited's Asset Resilience Ratio has changed over time. Read Orchid Pharma Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Orchid Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Orchid Pharma Limited (ORCHPHARMA) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs770.66 Million | 4.03% |
| Total Liquid Assets | Rs770.66 Million | 4.03% |
Asset Resilience Insights
- Limited Liquidity: Orchid Pharma Limited maintains only 4.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Orchid Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Orchid Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE |
Drug Manufacturers - Specialty & Generic | 1.38% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799 |
Drug Manufacturers - Specialty & Generic | 0.40% |
Orchid Pharma Limited Asset Resilience Ratio by Year (2004–2026)
Orchid Pharma Limited asset resilience ratio by year from 2004 to 2026. The table below shows the annual Asset Resilience Ratio data for Orchid Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 4.03% | Rs770.66 Million ≈ $8.33 Million |
Rs19.11 Billion ≈ $206.66 Million |
-5.17pp |
| 2025-03-31 | 9.21% | Rs1.55 Billion ≈ $16.81 Million |
Rs16.88 Billion ≈ $182.54 Million |
+9.15pp |
| 2024-03-31 | 0.06% | Rs9.23 Million ≈ $99.81K |
Rs15.54 Billion ≈ $168.05 Million |
-0.27pp |
| 2023-03-31 | 0.33% | Rs40.15 Million ≈ $434.16K |
Rs12.25 Billion ≈ $132.50 Million |
+0.33pp |
| 2022-03-31 | 0.00% | Rs59.00K ≈ $638.06 |
Rs11.11 Billion ≈ $120.10 Million |
-1.28pp |
| 2021-03-31 | 1.28% | Rs158.21 Million ≈ $1.71 Million |
Rs12.37 Billion ≈ $133.80 Million |
+1.28pp |
| 2020-03-31 | 0.00% | Rs122.00K ≈ $1.32K |
Rs14.60 Billion ≈ $157.88 Million |
-7.58pp |
| 2019-03-31 | 7.58% | Rs2.33 Billion ≈ $25.22 Million |
Rs30.77 Billion ≈ $332.77 Million |
-1.07pp |
| 2018-03-31 | 8.65% | Rs2.70 Billion ≈ $29.25 Million |
Rs31.25 Billion ≈ $338.00 Million |
+1.39pp |
| 2017-03-31 | 7.26% | Rs2.36 Billion ≈ $25.57 Million |
Rs32.56 Billion ≈ $352.08 Million |
+7.28pp |
| 2016-03-31 | -0.02% | Rs-6.73 Million ≈ $-72.80K |
Rs38.62 Billion ≈ $417.67 Million |
-0.44pp |
| 2011-03-31 | 0.42% | Rs171.78 Million ≈ $1.86 Million |
Rs40.71 Billion ≈ $440.21 Million |
-5.03pp |
| 2010-03-31 | 5.45% | Rs2.06 Billion ≈ $22.25 Million |
Rs37.74 Billion ≈ $408.10 Million |
+3.04pp |
| 2009-03-31 | 2.41% | Rs1.02 Billion ≈ $11.04 Million |
Rs42.34 Billion ≈ $457.89 Million |
-0.61pp |
| 2008-03-31 | 3.02% | Rs1.05 Billion ≈ $11.36 Million |
Rs34.84 Billion ≈ $376.81 Million |
-1.09pp |
| 2007-03-31 | 4.10% | Rs1.19 Billion ≈ $12.83 Million |
Rs28.91 Billion ≈ $312.65 Million |
-0.26pp |
| 2006-03-31 | 4.36% | Rs945.99 Million ≈ $10.23 Million |
Rs21.69 Billion ≈ $234.52 Million |
+0.73pp |
| 2005-03-31 | 3.64% | Rs659.20 Million ≈ $7.13 Million |
Rs18.12 Billion ≈ $196.01 Million |
+2.74pp |
| 2004-03-31 | 0.90% | Rs128.15 Million ≈ $1.39 Million |
Rs14.28 Billion ≈ $154.41 Million |
-- |
About Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, m… Read more